Related references
Note: Only part of the references are listed.A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
Satoko Kakiuchi-Kiyota et al.
LEUKEMIA (2022)
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
Gabrielle Leclercq et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Xinyi Xiao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Bispecific antibodies poised to deliver wave of cancer therapies
Cormac Sheridan
NATURE BIOTECHNOLOGY (2021)
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model
Jaya Lakshmi Thangaraj et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Epigenetic Regulation of NK Cell-Mediated Antitumor Immunity
Miaoran Xia et al.
FRONTIERS IN IMMUNOLOGY (2021)
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
Maxwell Y. Lee et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
Cai Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?
Arthur J. Van De Vyver et al.
CLINICAL CANCER RESEARCH (2021)
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
Lauric Haber et al.
SCIENTIFIC REPORTS (2021)
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
IL-13 is a driver of COVID-19 severity
Alexandra N. Donlan et al.
JCI INSIGHT (2021)
Tumor-infiltrating lymphocytes in the immunotherapy era
Sterre T. Paijens et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Yuying Liu et al.
SCIENCE IMMUNOLOGY (2020)
Pharmacological targeting of natural killer cells for cancer immunotherapy
Kiho Miyazato et al.
CANCER SCIENCE (2020)
Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice
Claire Godbersen-Palmer et al.
JOURNAL OF IMMUNOLOGY (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett et al.
BLOOD (2020)
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
Craig W. Freyer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Shih-Feng Cho et al.
CANCERS (2020)
Macrophage, the potential key mediator in CAR-T related CRS
Zhaonian Hao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies
Tobias Bald et al.
NATURE IMMUNOLOGY (2020)
Cytokines in CAR T Cell-Associated Neurotoxicity
Juliane Gust et al.
FRONTIERS IN IMMUNOLOGY (2020)
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
Ying Cheng et al.
CANCER BIOLOGY & MEDICINE (2020)
Targeting natural killer cells in solid tumors
Guillaume Habif et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Melanie Maerklin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Ji Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarha et al.
BLOOD ADVANCES (2018)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
S. Hipp et al.
LEUKEMIA (2017)
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jorg U. Schmohl et al.
CANCER RESEARCH AND TREATMENT (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma
Tong Wang et al.
CANCER LETTERS (2016)
T helper 2 and T follicular helper cells: Regulation and function of interleukin-4
Anupama Sahoo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
TRAIL+ NK Cells Control CD4+ T Cell Responses during Chronic Viral Infection to Limit Autoimmunity
Iona S. Schuster et al.
IMMUNITY (2014)
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma
Achim Rothe et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells
Daniel A. Vallera et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion
Dimitra Peppa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Natural killer cells act as rheostats modulating antiviral T cells
Stephen N. Waggoner et al.
NATURE (2012)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore et al.
BLOOD (2011)
Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes
I-Fang Lee et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Activation, coactivation, and costimulation of resting human natural killer cells
Yenan T. Bryceson et al.
IMMUNOLOGICAL REVIEWS (2006)
Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome
AA Grom et al.
JOURNAL OF PEDIATRICS (2003)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
A Löffler et al.
BLOOD (2000)
Share Paper
